News
IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia (2026-04-20)
22+ hour, 8+ min ago (152+ words) The authorization, granted under the oversight of the Fondo Nacional de Estupefacientes (FNE), provides IGC Pharma with a regulated capability to work with psilocybin, positioning the Company within an expanding area of scientific and investor interest. The Company believes it…...
Protagenic Therapeutics Advances PT00114 into Multiple-Dose Phase 1 Trial; Positioning for Phase 2 in Stress & Mood Disorders (2025-08-21)
8+ mon, 4+ hour ago (162+ words) Dosing Completion Expected by End of August; Phase 2 Trial Expected to Begin in 1 Q 2026 Current treatments leave more than half of patients without adequate relief and are burdened by significant side effects. "Initiating the multiple-dose trial of PT00114 marks a pivotal…...
Neurocrine Biosciences fails mid-stage study of depression drug
5+ mon, 1+ week ago (121+ words) Founded in 2004, Seeking Alpha is an industry-leading financial research platform powered by one of the world's largest investing communities. We bridge the gap between financial information and actionable insight by providing unrivaled coverage on all asset classes and access to…...
Teva long-acting antipsychotic Uzedy gains indication for bipolar disorder
6+ mon, 1+ week ago (146+ words) Founded in 2004, Seeking Alpha is an industry-leading financial research platform powered by one of the world's largest investing communities. We bridge the gap between financial information and actionable insight by providing unrivaled coverage on all asset classes and access to…...
Tonix to advance cyclobenzaprine into phase 2 for depression
6+ mon, 1+ week ago (118+ words) Founded in 2004, Seeking Alpha is an industry-leading financial research platform powered by one of the world's largest investing communities. We bridge the gap between financial information and actionable insight by providing unrivaled coverage on all asset classes and access to…...
Atai: Inidascamine Trial Failure Doesn't Matter In Main Psychedelic Pipeline Focus (ATAI)
8+ mon, 3+ week ago (368+ words) Founded in 2004, Seeking Alpha is an industry-leading financial research platform powered by one of the world's largest investing communities. We bridge the gap between financial information and actionable insight by providing unrivaled coverage on all asset classes and access to…...